These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 4546783)

  • 21. Time and dose influences on the behavioral effects of L-DOPA and 5-hydroxytryptophan after inhibition of extracerebral decarboxylase.
    Gronan RJ
    Pharmacol Biochem Behav; 1975; 3(2):161-6. PubMed ID: 1079949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence that taste aversion learning induced by l-5-hydroxytryptophan is mediated peripherally.
    Ervin GN; Carter RB; Webster EL; Moore SI; Cooper BR
    Pharmacol Biochem Behav; 1984 May; 20(5):799-802. PubMed ID: 6610880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human pharmacokinetics of long term 5-hydroxytryptophan combined with decarboxylase inhibitors.
    Magnussen I; Van Woert MH
    Eur J Clin Pharmacol; 1982; 23(1):81-6. PubMed ID: 6182005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction of tetrahydropapaveroline with inhibition of dopa-decarboxylase by Ro 4-4602 in brain: effects on alcohol drinking in the rat.
    Miñano FJ; McMillen BA; Myers RD
    Alcohol; 1989; 6(2):133-7. PubMed ID: 2713086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of a minor pathway of L-dopa metabolism in the intestinal lumen using a decarboxylase inhibitor (Ro 4-4602).
    Bakke OM; Scheline RR
    J Pharm Pharmacol; 1974 May; 26(5):377-9. PubMed ID: 4152920
    [No Abstract]   [Full Text] [Related]  

  • 26. L-5-hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression.
    Zmilacher K; Battegay R; Gastpar M
    Neuropsychobiology; 1988; 20(1):28-35. PubMed ID: 3265988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Muricidal block produced by 5-hydroxytryptophan and various drugs.
    Kulkarni AS
    Life Sci; 1968 Feb; 7(3):125-8. PubMed ID: 5300261
    [No Abstract]   [Full Text] [Related]  

  • 28. 5-Hydroxytryptophan attenuates somatic signs of nicotine withdrawal.
    Ohmura Y; Jutkiewicz EM; Yoshioka M; Domino EF
    J Pharmacol Sci; 2011; 117(2):121-4. PubMed ID: 22001627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Behavioral and prolactin responses to 5-hydroxytryptophan in rats treated during development with 5,7-dihydroxytryptamine.
    Breese GR; Vogel RA; Kuhn CM; Mailman RB; Mueller RA; Schanberg SM
    Brain Res; 1978 Oct; 155(2):263-75. PubMed ID: 308387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence for inhibition by brain serotonin of mouse killing behaviour in rats.
    Di Chiara G; Camba R; Spano PF
    Nature; 1971 Sep; 233(5317):272-3. PubMed ID: 4938370
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)].
    Yoshimine N; Kuzuya F; Mori K; Sakamoto N
    Nihon Ronen Igakkai Zasshi; 1978 Nov; 15(6):566-73. PubMed ID: 732010
    [No Abstract]   [Full Text] [Related]  

  • 32. Action of probenecid on the central nervous system of the rabbit. II. Potentiation of 5-hydroxytryptophan-induced hyperthermia and suppression of this effect by a decarboxylase inhibitor (Ro4-4602).
    Gardey-Levassort C; Olive G; Lechat P
    Pharmacology; 1974; 11(5):267-77. PubMed ID: 4546714
    [No Abstract]   [Full Text] [Related]  

  • 33. DL-5-hydroxytryptophan-induced changes in central monoamine neurons after peripheral decarboxylase inhibition.
    Fuxe K; Butcher LL; Engel J
    J Pharm Pharmacol; 1971 Jun; 23(6):420-4. PubMed ID: 4397180
    [No Abstract]   [Full Text] [Related]  

  • 34. Skeletal changes induced by dopa decarboxylase inhibitor in rats.
    Tanaka C; Tanaka S; Itokawa Y; Takaori S
    Jpn J Pharmacol; 1973 Feb; 23(1):123-5. PubMed ID: 4541614
    [No Abstract]   [Full Text] [Related]  

  • 35. Behavior and biochemical effects of preferentially protecting monoamines in the brain against the action of reserpine.
    Butcher LL; Rhodes DL; Yuwiler A
    Eur J Pharmacol; 1972 May; 18(2):204-12. PubMed ID: 4537669
    [No Abstract]   [Full Text] [Related]  

  • 36. Inhibition of tyrosine-3-monooxygenase by benserazide.
    Reinhard JF; Shearin MD
    Biochem Pharmacol; 1990 May; 39(9):1489-91. PubMed ID: 1970732
    [No Abstract]   [Full Text] [Related]  

  • 37. Behavioral and biochemical effects of L-dopa after peripheral decarboxylase inhibition.
    Butcher LL; Engel J
    Brain Res; 1969 Sep; 15(1):233-42. PubMed ID: 5807767
    [No Abstract]   [Full Text] [Related]  

  • 38. Differentiation between the stimulus effects of l-5-hydroxytryptophan and LSD.
    Cunningham KA; Callahan PM; Appel JB
    Eur J Pharmacol; 1985 Jan; 108(2):179-86. PubMed ID: 3156756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperleptinemia elicited by the 5-HT precursor, 5-hydroxytryptophan in mice: involvement of insulin.
    Yamada J; Sugimoto Y; Ujikawa M; Goko H; Yagura T
    Life Sci; 2003 Sep; 73(18):2335-44. PubMed ID: 12941435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Central versus peripheral effects on temperature preference and body temperature following alteration of 5-HT in maturing mice.
    Goodrich C; Lechner R; Slone W
    Physiol Behav; 1989 Aug; 46(2):203-9. PubMed ID: 2602460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.